Latest Breaking News On - ஒன்றுபட்டது நிலை தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் - Page 1 : vimarsana.com

A medic shows a vial containing doses of Covaxin (PTI Photo) HYDERABAD: In yet another booster shot of endorsement for India’s first indigenously developed Covid-19 vaccine Covaxin, the United States’ National Institutes of Health has said that the vaccine is able to effectively neutralise the Alpha and Delta variants of SARS-CoV-2. “Results from two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralize the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the United Kingdom and India, respectively,” NIH said. Citing Phase 2 trial published in The Lancet Infectious Diseases, NIH said the results indicate that Covaxin is “safe and well-tolerated” and also pointed out that unpublished interim results from the Phase-3 trial conducted on 25,800 participants indicate that the vaccine has 78% efficacy against symptomatic disease, 100% efficacy against severe Covid-

United statesAndhra pradeshUnited kingdomCovaxin covidAnthonys fauciUnited states food drug administration for covaxinNational institutes of healthNational institute of allergyAdjuvant development programUnited state national institutes of healthUnited state national institutesLancet infectious diseasesNational institutesNational instituteInfectious diseasesBharat biotech